NASDAQ:LSTA Lisata Therapeutics (LSTA) Stock Price, News & Analysis $3.10 -0.17 (-5.20%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$3.02▼$3.3450-Day Range$2.75▼$3.7052-Week Range$1.95▼$3.83Volume8,603 shsAverage Volume13,784 shsMarket Capitalization$25.75 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Lisata Therapeutics alerts: Email Address Lisata Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside383.9% Upside$15.00 Price TargetShort InterestHealthy0.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.97) to ($2.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.29 out of 5 starsMedical Sector290th out of 910 stocksPharmaceutical Preparations Industry123rd out of 426 stocks 3.5 Analyst's Opinion Consensus RatingLisata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageLisata Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Lisata Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.11% of the float of Lisata Therapeutics has been sold short.Short Interest Ratio / Days to CoverLisata Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lisata Therapeutics has recently decreased by 24.49%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLisata Therapeutics does not currently pay a dividend.Dividend GrowthLisata Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LSTA. Previous Next 2.5 News and Social Media Coverage News SentimentLisata Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lisata Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Lisata Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lisata Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.60% of the stock of Lisata Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.94% of the stock of Lisata Therapeutics is held by institutions.Read more about Lisata Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Lisata Therapeutics are expected to grow in the coming year, from ($2.97) to ($2.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lisata Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lisata Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLisata Therapeutics has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lisata Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsDon’t buy a single stock before you’ve seen this...During the 2020 Covid Crash he called for a massive "snap back rally" - eleven days before the S&P bottomed out. Now, he's coming out with another major warning.Click here for his latest emergency briefing >>> About Lisata Therapeutics Stock (NASDAQ:LSTA)Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Read More LSTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LSTA Stock News HeadlinesSeptember 5 at 6:38 PM | finance.yahoo.comLisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of CholangiocarcinomaSeptember 5 at 10:58 AM | proactiveinvestors.comLisata Therapeutics' certepetide receives Orphan Drug Designation for cholangiocarcinomaSeptember 8, 2024 | Paradigm Press (Ad) Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.September 5 at 8:00 AM | globenewswire.comLisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of CholangiocarcinomaAugust 22, 2024 | finance.yahoo.comWill Lisata Therapeutics (NASDAQ:LSTA) Spend Its Cash Wisely?August 13, 2024 | markets.businessinsider.comLisata Therapeutics: Strong Buy Rating on Robust Financials and Promising Clinical TrialsAugust 13, 2024 | msn.comLisata Therapeutics, Inc. (NASDAQ:LSTA) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | investorplace.comLSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q2 2024September 8, 2024 | Paradigm Press (Ad) Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.August 12, 2024 | markets.businessinsider.comLisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 12, 2024 | proactiveinvestors.comLisata Therapeutics coming off strong 2Q performance, CEO saysJuly 27, 2024 | proactiveinvestors.comLisata Therapeutics CMO details pancreatic cancer research collaboration with Haystack Oncology - ICYMIJuly 22, 2024 | benzinga.comLisata Therapeutics (NASDAQ:LSTA) Stock Quotes, Forecast and News SummaryJuly 19, 2024 | markets.businessinsider.comHaystack Oncology And Lisata Therapeutics Partner To Evaluate Efficacy Of Pancreatic Cancer TherapyJuly 19, 2024 | finance.yahoo.comHaystack Oncology, Lisata Therapeutics Collaborate on Pancreatic Cancer TherapyJuly 19, 2024 | msn.comEXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy EfficacyJuly 18, 2024 | proactiveinvestors.comLisata Therapeutics partners with Haystack Oncology to advance pancreatic cancer therapy researchJuly 18, 2024 | globenewswire.comHaystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer TherapySee More Headlines Receive LSTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lisata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/08/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LSTA CUSIPN/A CIK320017 Webwww.caladrius.com Phone(908) 842-0100Fax646-514-7787Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$15.00 Low Stock Price Target$15.00 Potential Upside/Downside+383.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-46.48% Return on Assets-41.40% Debt Debt-to-Equity RatioN/A Current Ratio9.42 Quick Ratio9.42 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.57 per share Price / Book0.68Miscellaneous Outstanding Shares8,307,000Free Float6,513,000Market Cap$25.75 million OptionableNot Optionable Beta1.21 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. David J. Mazzo B.A. (Hons) (Age 67)B.Sc. (Hons.), M.Sc., Ph.D., President, CEO & Director Comp: $1.16MDr. Kristen K. Buck M.D. (Age 50)Executive VP of R&D and Chief Medical Officer Comp: $938.42kMr. James Nisco (Age 53)Senior VP of Finance, Treasurer, CAO & Principal Financial and Accounting Officer Mr. Tariq ImamVice President of Business Development & Operations and Corporate CounselMr. Gregory S. BerkinChief Information OfficerMr. John D. MendittoVice President of Investor Relations & Corporate CommunicationsMs. Gail Holler (Age 65)Vice President of Human Resources Dr. William K. Sietsema Ph.D. (Age 68)Vice President of Global Regulatory Affairs Comp: $350.55kMore ExecutivesKey CompetitorsKentucky First Federal BancorpNASDAQ:KFFBOrgenesisNASDAQ:ORGSNeos TherapeuticsNASDAQ:NEOSVistagen TherapeuticsNASDAQ:VTGNSagimet BiosciencesNASDAQ:SGMTView All CompetitorsInstitutional OwnershipDimensional Fund Advisors LPBought 5,639 shares on 8/9/2024Ownership: 0.209%View All Institutional Transactions LSTA Stock Analysis - Frequently Asked Questions How have LSTA shares performed this year? Lisata Therapeutics' stock was trading at $2.73 on January 1st, 2024. Since then, LSTA shares have increased by 13.6% and is now trading at $3.10. View the best growth stocks for 2024 here. How were Lisata Therapeutics' earnings last quarter? Lisata Therapeutics, Inc. (NASDAQ:LSTA) released its quarterly earnings data on Monday, August, 12th. The company reported ($0.61) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.14. Who are Lisata Therapeutics' major shareholders? Lisata Therapeutics' top institutional shareholders include Dimensional Fund Advisors LP (0.21%). How do I buy shares of Lisata Therapeutics? Shares of LSTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LSTA) was last updated on 9/8/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredExposed: 3 CENT Crypto to Explode September 23rd?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
